Encompass Health raises 2025 guidance as Q2 revenue rises 12.0% to $1.46 billion
Encompass Health reported second-quarter 2025 net operating revenue of $1,457.7 million, up 12.0% from $1,301.2 million a year earlier, and diluted earnings per share from continuing operations of $1.40, up from $1.13. The company raised its full-year 2025 guidance for net operating revenue, adjusted EBITDA and adjusted earnings per share, which gives shareholders a higher outlook for the year.
Key points
- Q2 2025 net operating revenue was $1,457.7 million, up 12.0%; diluted EPS from continuing operations was $1.40 versus $1.13.
- Adjusted EPS was $1.40 versus $1.11 a year earlier; adjusted EBITDA was $318.6 million, up 17.2%.
- Full-year 2025 adjusted EPS guidance rose to $5.12 to $5.34 from $4.85 to $5.10; net operating revenue guidance rose to $5,880 to $5,980 million.
- Management will discuss results on an earnings call at 10:00 a.m. Eastern Time on August 5, 2025.
The filing
Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.